Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Alnylam, Medicines Company Announce Plans for Phase 3 Inclisiran Studies

By Ryan Bushey | April 26, 2017

The Medicines Company and Alnylam Pharmaceuticals on Wedsenday outlined the next step in the development process for investigational RNAi therapy inclisiran. 

Both companies announced an agreement was made with The Food and Drug Administration on a Phase 3 program evaluating the drug’s efficacy in treating atherosclerotic cardiovascular disease (ASCVD) and familial hypercholesterolemia (FH).

The first study will enroll an approcimate 3,000 patients where investigators will randomly assign treatment so 1,500 patients will either recieve a 300 miligram dose of inclisiran four times over an 18 month period while the other half will receive the placebo, according to Xconomy. The main goal of this study is to assess the drug’s ability to reduce levels of low-density lipoprotein cholesterol (LDL-C), otherwise known as “bad” cholesterol.

Also, the partners will implement a seperate cardiovascular outcomes trial enrolling an approximate 14,000 patients diagnosed with ASCVD and/or risk equivalents like diabetes with the goal of analyzing the drug’s ability to lower the risk of heart attacks or strokes. Trials of this nature tend to take a few years, but investigators will determine if inclisiran acheived its primary efficacy endpoint based on a mix of coronary heart disease death, non-fatal myocardial infarction and fatal and non-fatal ischemic stroke.

“We are grateful to the FDA for its expertise, advice and support. Cardiovascular disease is a serious threat to the health of Americans, and it is clear that the FDA is committed to facilitating the development and approval of effective and safe drugs to address this important public health problem,” said the CEO of The Medicines Company Clive Meanwell, M.D., Ph.D., in a statement “Based on data from our Phase II ORION-1 study and the previous Phase I study – both published in The New England Journal of Medicine – we are confident that inclisiran reduces LDL-C meaningfully. We have also been highly encouraged by the safety data in these prior studies. Furthermore, inclisiran’s highly-differentiated dosing schedule has the potential to transform the burden placed on millions of patients who so badly need to lower LDL-C levels.

The hope is that inclisiran’s mechanism of action turning off the synthesis of PCSK9, the protein regulator of LDL receptor metabolism, in the liver instead of the blood combined with a more convenient dosing schedule could make it a viable alternative compared to products like Amgen’s Repatha.

Alnylam and Medicines Co. hope to file for regulatory approval sometime in 2019, but data from the outcomes trial could be part of a seperate supplemental NDA. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE